Defined as a combination of metabolic and electrolyte abnormalities occurring spontaneously or following initiation of cytotoxic treatment in patients with cancer. It is characterized by excessive cell lysis.
Most commonly associated with highly proliferative, bulky, chemosensitive malignancies, such as lymphomas and leukemias.
Laboratory TLS is characterized by a combination of any 2 of hyperuricemia, hyperphosphatemia, hyperkalemia, or hypocalcemia. Clinical TLS is defined as laboratory TLS with either an increased serum creatinine, cardiac arrhythmia, seizure activity, or sudden death.
Identification of high-risk patients and appropriate preventive management significantly reduces the risk of developing the syndrome. Vigorous hydration in combination with hypouricemic agents constitutes the cornerstone of both prevention and treatment.
Epocrates, Inc. All Rights Reserved.
Epocrates iPhone Epocrates Android Epocrates Palm Epocrates Free Download
Epocrates Institutional Sales Epocrates Market Research Epocrates CME Epocrates Mobile Resource Centers Epocrates Clinical Content